Clinical Trial

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 4 locations 2026-08-11
Trial Details
NCT Number NCT07545811
Lead Sponsor Janux Therapeutics
Conditions Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Enrollment 43 participants
Start Date 2026-04-15
Primary Completion 2028-05 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-10